Eric Carter

Eric Carter, M.D., Ph.D. has over 20 years of experience as both a physician and pharmaceutical industry executive, specializing in research and development as well as commercialization across multiple therapeutic areas. Dr. Carter previously served as Senior Vice President, Chief Medical Officer, Global Head of Clinical and Non-clinical Development of Allergan, Inc. from 2011 through its acquisition by Actavis Pharmaceuticals in 2015, where he led preclinical and global clinical development and operations in ophthalmology, dermatology, urology, CNS, and plastic surgery. Dr. Carter led Allergan through 11 drug candidate approvals during his tenure.

Prior to Allergan, Dr. Carter served as Chief Science Officer, Head of R&D and Chief Medical Officer of King Pharmaceuticals from 2007 until the company was acquired by Pfizer in 2011. Prior to King, Dr. Carter worked for Glaxo Wellcome and GSK where he held positions of increasing responsibility in global clinical development and medical affairs. Dr. Carter began his medical career at the University of North Carolina, Chapel Hill where he held board certifications in Internal Medicine, Gastroenterology and Hepatology and Clinical Nutrition.

Dr. Carter currently serves as Chairman of the Scientific Advisory Board of AEON Biopharma and serves on the Board of Directors of Bioniz Therapeutics. He received his M.D. from the University of Miami, FL and his Ph.D. from the University of Cambridge, England.